Improving CD34+ Yields Leads to a Robust and Reproducible Feeder-Free Human iNK Differentiation Process

Natural killer (NK) cells offer great potential for cancer immunotherapies targeting both hematological and solid tumors. Despite their therapeutic promise, generating homogeneous cell populations at clinically relevant numbers has proven challenging. Current NK cell sources from umbilical cord and peripheral blood are not easily expanded and tend to yield heterogenous populations.

Human iPSC-derived NK cells (iNKs) offer a solution, but many differentiation protocols rely on xenogenic feeder cells which pose challenges for patient safety and the resulting cells lack robustness.

To overcome this, we developed a feeder free differentiation protocol to generate iNKs at scale, increasing reproducibility and uniformity of the cell cultures, for use in allogeneic cancer therapy.

Download this iNK cell differentiation poster to learn how:

• CD34⁺ hematopoietic stem cells were optimized prior to downstream NK differentiation to improve iNK yields
• L562 feeder cells were substituted during iNK expansion to produce a feeder-free iNK workflow
• The fold expansion and killing activity of iNK cells compared to PBMC-derived NK cells